University of British Columbia

Simon Fraser University

Artem Tcherkassov

Paul Rennie

Devki Nandan

Neil E Reiner

Robert N Young

Fuqiang Ban

Christophe M Andre

Kriti Singh

Kateryna Dunayenko

Anh-tien Ton

Kush Dalal

Eric J J Leblanc

Anton V Tverdokhlebov

Nada Lallous

Evgeniia Bogomol

Helene Morin

Eric Joseph Jean LeBlanc

Paul S Rennie

Huifang Li

Sergiy Babiy

Lavinia A Carabet

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith

This invention provides compound having a structure of Formulas:  Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide.

Binding Function 3 (BF3) site compounds as therapeutics and methods for their use

This invention provides compound having a structure of Formulas: Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide. 

[object Object]

A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or bladder cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds are also described.

Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use

A compound capable of specifically binding to pathogen EF-1&#x3b1; but not host EF-1&#x3b1;, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22.

Diagnosis and treatment of infectious diseases through indel-differentiated proteins

Apparatus, methods, media, signals and data structures for protein sequence analysis are disclosed. A method includes identifying, from among a first group of aligned protein sequences having at least a threshold degree of alignment with a first protein sequence, a second group of at least one of the aligned sequences having at least one insertion or deletion ('indel') relative to the first protein sequence satisfying a predefined condition. The apparatus may include a processor circuit configured to carry out the method.

Methods and apparatus for protein sequence analysis

Growing community of inventors

Vancouver, Canada

Artem Tcherkassov